Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.
Polypodium leucotomos extract may improve short-term quality of life in patients with erythropoietic protoporphyria who do not fully respond to afamelanotide, but larger studies are needed to confirm these results.
Where it sits
this study against the rest of the afamelanotide corpusSummary and findings
This study evaluated the safety and efficacy of Polypodium leucotomos extract (PLE) as an adjunctive therapy in patients with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) who had ongoing symptoms despite standard afamelanotide treatment. Eight adults received 480 mg of PLE daily for 4 months. Statistically significant improvements in quality of life (QoL) were observed at Day 60 but not at Day 120.
Abstract
Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) cause severe photosensitivity, resulting in significant quality of life (QoL) impairment. This study aims to evaluate the safety and efficacy of Polypodium leucotomos extract (PLE) as an adjunctive therapy in patients with persistent symptoms despite standard dosing of afamelanotide. In this prospective single-center cohort study, eight adults with confirmed EPP or XLP and ongoing symptoms despite regular afamelanotide implants every 2 months were enrolled. Participants received 480 mg oral PLE daily for 4 months. QoL and symptom severity were measured using questionnaires at baseline, Day 60, and Day 120. Six participants completed the study. Statistically significant improvements in QoL were observed on Day 60 (p = 0.014), but not at Day 120 (p = 0.152). Half of participants reported reduced reaction severity. No adverse events occurred. Adjunctive PLE improved short-term QoL in participants with incomplete symptom control on afamelanotide alone and was well tolerated. Larger studies are warranted.
Background
This paper addresses the challenge of managing severe photosensitivity in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), conditions known to significantly impair quality of life (QoL). Previous treatments, including afamelanotide, may not fully alleviate symptoms for all patients. The exploration of adjunctive therapies like Polypodium leucotomos extract (PLE) is essential to improve patient outcomes.
Methods
This was a prospective single-center cohort study involving eight adults with confirmed EPP or XLP who experienced ongoing symptoms despite regular afamelanotide implants every 2 months. Participants received 480 mg of oral PLE daily for 4 months. QoL and symptom severity were assessed using questionnaires at baseline, Day 60, and Day 120.
Results
At Day 60, a statistically significant improvement in QoL was observed (p=0.014). However, this improvement was not maintained at Day 120 (p=0.152). Half of the participants reported a reduction in reaction severity, and no adverse events were reported throughout the study.
Interpretation
The findings suggest that while PLE may provide short-term benefits in QoL for patients with incomplete symptom control on afamelanotide, the lack of sustained improvement raises questions about the clinical significance of these results. The small sample size and single-center design limit the robustness of the conclusions, and further research is needed to confirm these findings in larger, more diverse populations.
Key findings
- Statistically significant improvement in QoL on Day 60, p=0.014.
- No statistically significant improvement in QoL on Day 120, p=0.152.
- Half of participants reported reduced reaction severity.
- Six participants completed the study.
Limitations
- small sample size of n=8
- single-center study limits generalizability
- short follow-up duration of 4 months
- no control group for comparison